1. Introduction {#sec1}
===============

Noonan syndrome (\[NS1, OMIM [163950](163950){#intref0010}\]) is a common autosomal dominant disorder characterized by short stature, congenital heart disease, facial dysmorphia and other features such as cryptorchidism, bleeding diathesis, skeletal malformations and mild cognitive delays with variable expressivity. The prevalence of this disorder is estimated to be 1/1000--2500 live births [@bib1], [@bib2], [@bib3]. The varied clinical manifestations observed in Noonan syndrome patients (facial, skeletal cardiac, and hematological, among others) are a result of the involvement of the RAS MAP kinase molecular signaling pathway, as will be shown below.

The previous updates and reviews in the literature have thoroughly discussed Noonan syndrome, often focusing on diagnostic evaluations, clinical guidelines, and management with treatment options, which have amply helped clinicians provide the best care for Noonan syndrome children. The molecular aspects of this disorder have been approached in these reviews progressively with genetic advances. However, considering the fast advances and consecutive progress being made in the physiopathology and genetic studies of Noonan syndrome, it seems important to gather these findings in one paper to help the audience of clinicians and geneticists have a full view of recent advances in the molecular etiology of Noonan syndrome, as well as an authentic prevalence of the mutational rates of its causing-genes. Therefore, this review provides, in the first part, an update on the molecular aspect of the disease, in which we summarize the data concerning clinical features frequently observed, then focus on the molecular etiology, the inheritance pattern and the genetic counseling that should be given to patients. In the second part of this review, we establish and discuss the mutational rate reported up to now in most genes involved in Noonan syndrome.

2. Review {#sec2}
=========

2.1. Clinical features and diagnosis {#sec2.1}
------------------------------------

The diagnosis of Noonan syndrome is based primarily on the clinical features that have been established from the very beginning through several clinical studies that have meticulously defined the criteria and signs of diagnosis [@bib1], [@bib2], [@bib3].

### 2.1.1. Dysmorphic face {#sec2.1.1}

The extreme variability of facial traits in Noonan syndrome from one individual to another makes the assessment of frequency difficult and not very meaningful. Furthermore, the dysmorphic signs could change within the same patient depending on his/her age, to be less perceptible in adulthood than earlier in childhood. The dysmorphology is characterized during the postnatal period by a tall forehead, low-set-posteriorly-rotated ears, a thickened helix, nerve deafness, hypertelorism, ptosis, down slanting palpebral fissures, epicanthal folds, deeply grooved philtrum, a high arched palate and triangular face, with a low posterior hairline and webbed neck. In adulthood, the facial features become more subtle, the eyes are less prominent, with a slightly elongated neck, wrinkled skin and high anterior hairline [@bib3], [@bib4], [@bib5].

### 2.1.2. Congenital heart defect {#sec2.1.2}

The cardiac features are well delineated and are estimated to be present in 50% up to 90% of Noonan syndrome patients [@bib6], [@bib7], [@bib8]. The most common congenital heart defects (CHD) are pulmonic stenosis (50--60%), hypertrophic cardiomyopathy (HCM) (20%) and atrial septal defect (6--10%) [@bib9], [@bib10]. The other CHDs such as ventricular septal defect, atrioventricular canal defect, and aortic coarctation are observed less frequently [@bib6], [@bib8], [@bib11]. Electrocardiographic abnormalities were reported in 87% of patients [@bib3]. Electrocardiograms display wide QRS complexes with a predominant negative pattern in the left precordial leads, a left axis deviation and giant Q waves [@bib9], [@bib10], [@bib11].

### 2.1.3. Growth/short stature {#sec2.1.3}

Weight and height are normal at birth. However, during childhood and at puberty, short stature becomes a prominent common sign of Noonan syndrome. In one series reported by Nora et al, the prevalence of Noonan children with height below the 3rd percentile is approximately 83% [@bib12]. In another study, pubertal growth was found to be delayed by almost two years and the mean height was in the 3rd percentile, with female and male average heights of 151 cm and 161 cm respectively, and the average bone age delayed by two years [@bib8].

### 2.1.4. Skeletal defects {#sec2.1.4}

A chest deformity characterized by superior pectus carinatum and inferior pectus excavatum is observed in up to 95% of Noonan syndrome patients. Half (50%) have cubitus valgus and 30% have a clinobrachydactyly. The other orthopedic features, such as thoracic scoliosis, talipes equinovarus or radiolunar synostosis, are observed less often [@bib3], [@bib7].

### 2.1.5. Bleeding defect {#sec2.1.5}

The coagulation defect is the most common hematologic disorder in Noonan syndrome patients. Approximately 55% of patients have mild to moderate abnormal bleeding, whereas only 3% have major abnormal bleeding [@bib3].

### 2.1.6. Genito-urinary {#sec2.1.6}

Altered spermatogenesis and cryptorchidism are observed in 60--80% of patients [@bib13]. Ten percent of patients have renal abnormalities that often include renal pelvis dilatation [@bib3].

### 2.1.7. Ophthalmological features {#sec2.1.7}

Approximately 55% of Noonan syndrome patients have an abnormal ophthalmological test [@bib3]. The frequent abnormalities are refractive errors (61--70%), strabismus (48--63%), amblyopia (33%) and anterior segment changes (63%) [@bib14], [@bib15].

### 2.1.8. Other features {#sec2.1.8}

Other features have also been reported, including lymphatic abnormalities, hematological malignancy, giant cell lesions and cognitive disability, among others [@bib16], [@bib17], [@bib18], [@bib19].

2.2. Genetic diagnosis and molecular etiology {#sec2.2}
---------------------------------------------

As shown above, Noonan syndrome is a heterogeneous disorder with various clinical features ranging from facial dysmorphology to short stature and bleeding defects up to congenital heart disease. Those features have been demonstrated by several studies to be the yield of diverse molecular and physiological mechanisms, some of which are well known, while others need to be further elucidated.

The molecular etiology of Noonan syndrome has been established first by the study of two large Noonan syndrome families using linkage analysis [@bib20], [@bib21], [@bib22]. These studies suggested that the concerned locus is located in the 12q24 region. Based on these data, and the data suggesting the involvement of SHP-2 in the signaling pathways that control semilunar valvulogenesis [@bib23], and by means of a positional candidacy approach, Tartaglia et al [@bib24] suggested *PTPN11* to be a Noonan syndrome candidate gene, and confirmed this hypothesis by bidirectionally sequencing the fifteen exons of *PTPN11*, which have shown mutations in 50% of the studied cohort.

### 2.2.1. *PTPN11* (protein-tyrosine phosphatase, nonreceptor-type 11) {#sec2.2.1}

The *PTPN11* gene (\[OMIM [176876](176876){#intref0015}\]) ([Fig. 1](#fig1){ref-type="fig"}A) is organized into three domains: the N-amino terminal src-homology 2 domain (N-SH2) and the phosphotyrosine phosphatase (PTP) domain, which are the most commonly mutated domains; and the C-amino terminal src-homology 2 domain (C-SH2) and carboxy-terminal tail [@bib25], [@bib26].Figure 1Organization of Noonan syndrome causing genes and domains, **A**. PTPN11 exons and SHP-2 domains, **B**. SOS1 exons and domains, **C**. KRAS coding exons and domains. In most cases, the exon 4a is spliced out. **D**. RIT1 coding exons and domains. **E**. RAF1 coding exons and domains with the localization of Ser259 and Ser621 residues that is critical for RAF1 auto-inhibition. **F**. BRAF coding exons and domains. **G**. MAP2K1 coding exons and domains. C-SH2: C-amino-terminal src-homology 2, CR: Conserved Region, CRD: Cysteine-Rich Domain, DH: Dbl Homology, HF: Histone-like Fold, HL: Helical Linker, N-SH2: N- amino-terminal src-homology 2, PH: Pleckstrin Homology, Pr: Proline-riche motif, PTP: protein-tyrosine phosphatase, RBD: RAS binding domain, REM: RAS Exchange Motif, Sw: Switch.Figure 1

Protein SHP-2 coded by *PTPN11* was demonstrated to be involved in several developmental processes such as limb development, semilunar valvulogenesis, hemopoietic cell differentiation and mesodermal patterning [@bib23], [@bib27], [@bib28], [@bib29], and is widely expressed in several tissues such as the heart, muscles, and brain, in which SHP-2 modulates the cellular proliferation, migration or differentiation processes during the developmental stage [@bib30]. SHP-2 is a key element of the signaling molecular RAS-MAP Kinase cascade ([Fig. 2](#fig2){ref-type="fig"}). The latter is triggered when cytokines, hormones or growth factors bind to membrane receptors [@bib25], [@bib26], [@bib31]. Therefore, its disturbance may cause alterations of these tissues that lead to the aberrant phenotype shown in Noonan syndrome patients. This fact has been confirmed by De Rocca et al, has confirmed that the SHP-2 mutations in Noonan syndrome were associated with the inhibition of GH-induced IGF-1 via the hyperactivation of RAS/ERK1/2 in a mouse model, which lead to the short stature observed in Noonan syndrome [@bib32].Figure 2Localization of Noonan syndrome causing genes into the RAS-MAP kinase signal transduction pathway.Figure 2

On the molecular level, SHP-2 is a cytosolic phosphatase protein activated by the binding of a N-SH2 domain to phosphotyrosyl residue, which leads to the conformational change making the catalytic site (PTP) available to the phosphotyrosyl residue. In the absence of substrate, SHP-2 regains its inactive form in which N-SH2 interacts with PTP to hide the catalytic site [@bib33].

Most of the *PTPN11* mutations causing Noonan syndrome manifestations cluster in these two domains. The energy-based structured analysis suggests that *PTPN11* mutations disrupt the inactive conformation, resulting in the emergence of the catalytic site which triggers the phosphotyrosyl phosphatase activity in the absence of the ligand [@bib24].

Additionally, several screening studies were carried out to define *PTPN11* mutations in other populations and to highlight putative novel mutations. *PTPN11* mutations were significantly correlated to the manifestation of pulmonary stenosis observed in 45--70% of cases [@bib34], [@bib35].

Seven other genes from the RAS-MAP kinase pathway ([Fig. 2](#fig2){ref-type="fig"}) were demonstrated to be mutated and to cause Noonan syndrome.

### 2.2.2. *SOS1* (Son of Sevenless homolog 1) {#sec2.2.2}

At present, *SOS1* (\[OMIM [182530](182530){#intref0020}\]) is considered the second molecular cause of Noonan syndrome. Roberts et al reported that *SOS1* is responsible for approximately 20% of Noonan syndrome patients in the absence of *PTPN11* mutations [@bib36].

*SOS1* is a guanine exchange factor (GEF) with a major role in the RAS-MAP kinase pathway. It is mapped on the 2p22-p21 region and consists of 23 exons ([Fig. 1](#fig1){ref-type="fig"}B) [@bib37], [@bib38] coding for multiple domains containing: histone-like folds domain (HF), Dbl homology domains (DH) and Pleckstrin homology domains (PH) with the following regulatory function; RAS exchanging motif (REM) and Cdc25 domains with catalytic function; helical linker (HL) relating PH and REM, and the PolyProline region [@bib36], [@bib39].

It was reported that Noonan syndrome-causing *SOS1* was associated with a high prevalence of ectodermal abnormalities [@bib36], [@bib39], [@bib40], [@bib41].

In the RAS-MAP kinase molecular cascade, RAS protein is inactivated by hydrolyzing GTP to GDP via GTPase Activating Protein (GAP). To be reactivated, RAS protein needs to exchange bound GDP for GTP via *SOS1*.

It was suggested that the Dbl homology domain inhibits RAS-GEF activity by competing with RAS for binding to the REM-Cdc25 complex designated as an allosteric site, which stabilizes the inactive conformation [@bib42].

Most mutations cluster in these domains and lead to gain-of-function in the RAS-MAP kinase pathway by disrupting the auto-inhibition of *SOS1* RAS-GEF activity [@bib36], [@bib39], [@bib43].

Pulmonic stenosis was more frequently observed in patients with *SOS1* mutations (83.3%) than in those with *PTPN11* mutations [@bib34].

The RAS family (*KRAS*, *HRAS*, *NRAS* and *RIT1*) is a small GTPase protein family responsible of signal propagation through the RAS-MAP kinase cascade. It acts as a molecular switch cycling between an inactive GDP bound conformation and an active GTP bound conformation ([Fig. 2](#fig2){ref-type="fig"}) [@bib44], [@bib45].

### 2.2.3. *KRAS* (kirsten rat sarcoma viral oncogene homolog) {#sec2.2.3}

The *KRAS* (\[OMIM [190070](190070){#intref0025}\]) gene is mapped to the 12p12 region, and consists of 6 exons coding for the P loop, and switch I and switch II domains ([Fig. 1](#fig1){ref-type="fig"}C) [@bib46]. In response to a transduction signal generated from membrane receptor binding, *KRAS* regains its active bound GTP conformation via the guanine nucleotide exchange factor, and entails an activation cascade through the downstream effectors of RAS-MAP kinase (such as *RAF1*). *KRAS* has intrinsic GTPase activity, which, supported by RAS-GAPs (RAS-GTPase activating protein), hydrolyzes bound GTP to GDP to inactive itself [@bib44], [@bib45].

Lee et al and Schubbert et al have reported that *KRAS* mutations cause approximately 5% of Noonan syndrome cases in the absence of *PTPN11* mutations [@bib34], [@bib47]. These mutations lead to a gain in the function effect through the RAS-MAP kinase pathway by altering the intrinsic GTPase activity of *KRA*S and creating insensitivity to RAS-GAPs [@bib46], [@bib47].

Noonan syndrome patients with *KRAS* mutations were reported to have severe phenotypes with severe mental retardation [@bib46], [@bib47], [@bib48].

### 2.2.4. *NRAS* (neuroblastoma RAS viral oncogene homolog) {#sec2.2.4}

The *NRAS* (\[OMIM [164790](164790){#intref0030}\]) gene mapped on 1p13.2 comprises 6 coding exons [@bib49]. Cirstea et al have reported that *NRAS* mutations are involved in less than 1% of Noonan syndrome cases [@bib50].

### 2.2.5. *RIT1*(Ric-like protein without Caax motif 1) {#sec2.2.5}

Interestingly, in 2013, Aoki et al reported that mutations in *RIT1* (\[OMIM [609591](609591){#intref0035}\]) cause Noonan syndrome [@bib51]. *RIT1* is a member of the RAS subfamily of small GTPases ([Fig. 2](#fig2){ref-type="fig"}) [@bib52], and consists of 6 exons and is located in the 1q22 region ([Fig. 1](#fig1){ref-type="fig"}D).

Aoki et al identified nine missense mutations in seventeen individuals from 180 patients (9%) with Noonan syndrome or related disorders and without mutations in known Noonan syndrome-causing genes, and observed that the frequency of *RIT* mutations in the Noonan syndrome cohort was seemingly similar to the frequency of *RAF1* mutations. This finding was subsequently confirmed by Bertola et al, in 2014, who found the same prevalence (9%), and Gos et al, in 2014, who found a lower mutation rate (3.8%). Those mutation clusters in the G1, Switch I, and more frequently in Switch II domains, were proven to entail a significant activation of the RAS MAPK pathway by hyper-activating transcription factor *ELK1*. [@bib51], [@bib53], [@bib54].

Noonan syndrome patients with *RIT1* mutations were characterized by a high incidence of congenital heart disease (94%), especially hypertrophic cardiomyopathy (71%) and pulmonic stenosis (65%). The frequency of hypertrophic cardiomyopathy among *RIT1* mutation-positive patients is similar to that of *RAF1* mutation-positive subjects with Noonan syndrome, which leads to the conclusion that *RIT1* and *RAF1* interact with each other and have the same effect on cardiac development [@bib51], [@bib55], [@bib56].

The RAF family (*ARAF*, *BRAF* and *RAF1*) has an activation role upstream of the MEK-ERK cascade into the RAS-MAPK pathway ([Fig. 2](#fig2){ref-type="fig"}).

### 2.2.6. *RAF1* (v-raf-1 murine leukemia viral oncogene homolog 1) {#sec2.2.6}

*RAF1* (\[OMIM [164760](164760){#intref0040}\]) mutations cause 3--17% of Noonan syndrome cases. *RAF1* consists of 17 exons coding for multidomain protein that act as a serine--threonine kinase ([Fig. 1](#fig1){ref-type="fig"}E) [@bib55], [@bib57], [@bib58]. This protein comprises three conserved regions (CR): CR1 that contains the RAS binding domain (RBD) and cysteine-rich domain (CRD), which are both suggested to be involved in the negative regulation of *RAF1* by direct physical interaction [@bib59]; CR2, which is an important region where many *RAF1*-activating mutations and clusters lie. Eighty percent (80%) *RAF1* mutations in Noonan syndrome have HCM. It contains *Ser259* residue, which is critical to *RAF1* auto-inhibition [@bib55]; and the third conserved region (CR3) in the C-terminal region of *RAF1* that is responsible for catalytic activity [@bib55], [@bib57]. The *RAF1* inactive conformation is maintained via 14-3-3 protein dimers that bind to phosphorylated *Ser259* and *Ser621* in such a way that the catalytic site remains hidden [@bib60]. Mutations in these conserved residues or in its flanking residues (such as *Arg256* and *Pro261*, among others) prevent the 14-3-3 binding leading to an auto-inhibition fail and the activation of the RAS-MAP kinase cascade [@bib57].

Noonan syndrome-causing *RAF1* mutations were strongly correlated to hypertrophic cardiomyopathy. The latter was observed in 95% of Noonan syndrome patients, and seems to have an allele specificity that is associated with *Ser259* and *Ser612* mutations (*P* \< .0001) [@bib57].

In 2015, De Iriarte Rodrıguez et al proved that reduced levels of *RAF1* in mice may lead to hearing impairments [@bib61].

### 2.2.7. *BRAF* (V-Raf murine sarcoma viral oncogene homolog B1) {#sec2.2.7}

*BRAF* (\[OMIM [164757](164757){#intref0045}\]), a member of the RAF family, was proven to be involved in Noonan syndrome pathogenesis by enhancing *ERK* activation [@bib55], [@bib62]. However, the frequency of these mutations reported in a large cohort screening of Noonan syndrome patients were lower than those observed in *RAF1*, approximately 1.7--1.9%. These mutations cluster predominantly in conserved regions of CR1 and CR3 ([Fig. 1](#fig1){ref-type="fig"}F), but modestly increase kinase activity compared to *RAF1* [@bib34], [@bib63].

### 2.2.8. *MAP2K1* (mitogen activated protein kinase 1) {#sec2.2.8}

*MAP2K1* (\[OMIM [176872](176872){#intref0050}\]) is mapped to the 15q22 region and comprises 11 exons encoding the MEK protein, which is a dual-specificity kinase with a major protein kinase domain that activates the extracellular-signal-regulated (Erk) mitogen-activated protein (MAP) kinases ([Fig. 1](#fig1){ref-type="fig"}G) [@bib64].

Previous studies confirmed that MEK plays a crucial role in the embryonic developmental process, especially in cell migration and placental development [@bib64]. In 2007, Nava et al identified *MAP2K1* mutations in 4.2% of Noonan syndrome patients who are negative for *PTPN11* and *SO1* mutations [@bib65]. This finding proved that mutations in the MEK protein kinase domain increase MEK basal kinase activity. This hyperactivity entails an increased phosphorylation of the downstream targets (such as ERK1 and ERK2) [@bib66].

Recently, with the progress of molecular screening tools, whole genome sequencing (WGS) and whole exome sequencing (WES) have become increasingly used in the screening of developmental diseases. As a result, several novel Noonan syndrome-causing genes were highlighted in the last two years.

### 2.2.9. *SOS2* (Son of Sevenless homolog 2) {#sec2.2.9}

In 2015, Yamamoto et al reported that *SOS2* (\[OMIM [601247](601247){#intref0055}\]), the homolog of *SOS1*, is responsible of 4% of Noonan syndrome cases with no mutation in the genes previously associated with Noonan syndrome. *SOS1* and *SOS2* are 70% homologous. The reported mutations cluster in the DH domain, which plays a pivotal role in the stabilization of inactive conformation. Similar to *SOS1*, these mutations were associated with ectodermal defects [@bib67].

### 2.2.10. *LZTR1* (leucine-zipper-like transcription regulator 1) {#sec2.2.10}

In the same study, Yamamoto et al identified pathogenic mutations in a candidate gene not associated with the RAS/MAPK pathway, the *LZTR1* gene (\[OMIM [600574](600574){#intref0060}\]). The prevalence of these mutations in the same studied cohort was 8% [@bib67].

The *LZTR1* gene is located in 22q11.21 and consists of 21 exons and encodes a protein member of the BTB-kelch superfamily. It was suggested that this gene may have a crucial role in the control of fundamental cellular processes (such as the cell cycle and the regulation of chromatin conformation) [@bib68], [@bib69].

However, it is worth mentioning that *LZTR1* is already known to be associated with the Schwannomatosis, a form of neurofibromatosis [@bib70].

### 2.2.11. *A2ML1* (α-2-macroglobulin (A2M)-like-1) {#sec2.2.11}

Vissers et al carried out exome sequencing in one Noonan syndrome case-parent trio and found a *de novo* mutation affecting a highly conserved residue of *A2ML1* (\[OMIM [610627](610627){#intref0065}\]), encouraging them to screen an additional cohort of 155 Noonan syndrome patients. This study showed the involvement of *A2ML1* mutations in approximately 1% of Noonan syndrome subjects negative for the other NS major genes [@bib71]. *A2ML1* is a member of the α-macroglobulin superfamily, localized in 12p13 region with 35 coding exons. It acts as a protease inhibitor upstream of the MAPK pathway [@bib72]. Mutations in *A2ML1* are said to cause developmental defects, but the ways in which mutation affects the MAP kinase pathway needs to be further elucidated [@bib71].

Other genes carrying rare variants in a Noonan syndrome population were also highlighted recently, in particular, *RASA2*, *MAP3K8* and *SPRY* [@bib73].

### 2.2.12. Other causes {#sec2.2.12}

Some studies have suggested other causes of some Noonan syndrome manifestations that are not related to a particular gene. For instance, wide-spaced nipples, cryptorchidism and some traits of facial dysmorphia such as hypertelorism, down slanting palpebral fissures, ptosis and low-set posteriorly rotated ears are suggested to be the result of tissue migration disruption or organ displacement caused by lymphedema at the intrauterine stage. Webbing of the neck and prominence of the trapezius may result from cystic hygroma at early intrauterine stages [@bib74].

Recently, it was suggested that the impairment of testicular function responsible for delayed puberty or infertility is due to Sertoli and Leydig cell dysfunction rather than cryptorchidism [@bib75].

The coagulation defect in Noonan syndrome was explained by the fact that the genes causing Noonan syndrome interact with the regulation process of the genes involved in the coagulation pathway [@bib76].

2.3. Assessment of the mutation rate {#sec2.3}
------------------------------------

In the second part of this review, we gathered and discussed mutational screening data reported in previous studies, to produce valid frequencies and authentic conclusions about mutational rates in Noonan syndrome (\[NS, OMIM [163950](163950){#intref0070}\]).

### 2.3.1. Search strategy {#sec2.3.1}

The data gathered were extracted from original articles published up to now (December 2015) in the "PubMed", "ScienceDirect" and "Wiley Online Library" databases using the following key words:-"Noonan" in (\[Abstract\]).-"Noonan" in (\[Title/Abstract\]) AND "*PTPN11*" in (\[Title\]),-"Noonan" in (\[Title/Abstract\]) AND "*SOS1*" in (\[Title\]), and the same goes for the other genes (*RAF1*, *KRAS*, *BRAF*, *NRAS* and *RIT1*).

### 2.3.2. Inclusion criteria {#sec2.3.2}

From all of the articles gathered, we considered only studies comprising genetic screening of patient\'s series. We also considered clinical or endocrinological Noonan syndrome studies based initially on genetic screening. The genes considered in this part of the paper should have been screened by at least 3 studies meeting the inclusion criteria.

On the other hand, to determine the exact frequency of Noonan syndrome mutations, we excluded all data obtained from the screening of cohorts initially presenting with a particular condition (i.e., the mutational screening of Noonan syndrome patients with cardiac hypertrophy). The data gathered from the 82 included studies are summarized in [Table 1](#tbl1){ref-type="table"} [@bib77], [@bib78], [@bib79], [@bib80], [@bib81], [@bib82], [@bib83], [@bib84], [@bib85], [@bib86], [@bib87], [@bib88], [@bib89], [@bib90], [@bib91], [@bib92], [@bib93], [@bib94], [@bib95], [@bib96], [@bib97], [@bib98], [@bib99], [@bib100], [@bib101], [@bib102], [@bib103], [@bib104], [@bib105], [@bib106], [@bib107], [@bib108].Table 1Summary of the prevalence of Noonan syndrome-causing genes through previous studies.Table 1GenesN° of mutated subjects/total of subjects (% of mutations)% of gene in genetic etiologyFirst year of gene studyN° of studiesReferencesPTPN11814/1917 (42.5%)52.6200129[@bib19], [@bib24], [@bib34], [@bib35], [@bib58], [@bib77], [@bib83], [@bib84], [@bib85], [@bib86], [@bib87], [@bib88], [@bib89], [@bib90], [@bib91], [@bib92], [@bib93], [@bib94], [@bib95], [@bib96], [@bib97], [@bib98], [@bib99], [@bib100], [@bib101], [@bib102], [@bib103], [@bib104], [@bib105]SOS1242/1472 (16.4%)20.3200716[@bib19], [@bib34], [@bib36], [@bib39], [@bib43], [@bib58], [@bib78], [@bib79], [@bib97], [@bib98], [@bib102], [@bib103], [@bib104], [@bib105], [@bib106], [@bib107]RIT131/383 (8%)1020134[@bib51], [@bib53], [@bib54], [@bib73]RAF176/961 (8%)10200711[@bib34], [@bib55], [@bib56], [@bib57], [@bib58], [@bib78], [@bib79], [@bib98], [@bib103], [@bib105], [@bib107]KRAS31/1087 (2.8%)3.4200611[@bib46], [@bib47], [@bib48], [@bib58], [@bib65], [@bib79], [@bib89], [@bib98], [@bib102], [@bib103], [@bib105], [@bib108]BRAF19/815 (2.3%)2.820097[@bib34], [@bib63], [@bib78], [@bib98], [@bib103], [@bib105], [@bib108]NRAS10/1213 (0.8%)120104[@bib50], [@bib80], [@bib81], [@bib82]

### 2.3.3. Mutational rate of Noonan syndrome-causing genes {#sec2.3.3}

Through the analyzed data ([Table 1](#tbl1){ref-type="table"}), we found that *PTPN11* is the most studied gene in Noonan syndrome populations (29 studies vs. 16 studies or less for other genes). This may be because *PTPN11* was the first gene of the RAS MAPK pathway to be highlighted in 2001, whereas the second gene involved (*KRAS*) was found 5 years later, followed by SHP-2. Indeed, the second gene, *KRAS*, was known beforehand to be involved in malignancy disorders through somatic mutations, while its germline mutations were associated for the first time with Noonan syndrome in 2006.

Then, in 2007, three genes were highlighted, (*SOS1*, *RAF1* and *MAP2K1*), after which the other RAS/MAP kinase genes, *BRAF*, *NRAS* and *RIT1*, were proven to be involved in Noonan syndrome in more recent, in 2009, 2010 and 2013, respectively.

It should be noted that the chronology of the gene identification does not consistently occur in the "more involved" to "less involved" direction. Indeed, *RIT1*, which was discovered in 2013, was proven to be involved in 8% of cases. This frequency is much higher than the frequency of some genes (*BRAF*, *KRAS* and *NRAS*) that were found first, while their incidences do not exceed 3% (2.3%, 2.8% and 0.8%, respectively).

The first most common genetic cause of Noonan syndrome is still *PTPN11* mutations that are observed in 42.5% of Noonan syndrome patients. Those mutations constitute 52.6% of all mutations detected up to now ([Table 1](#tbl1){ref-type="table"}).

The second most-involved gene is *SOS1*, which is altered in 16.4% of patients. On the other hand, we found that *RIT1* and *RAF1* have the same prevalence (8%) and are the third most-involved genes.

Taken together, *PTPN11*, *SOS1*, *RAF1* and *RIT1* cover 93% of reported mutations ([Table 1](#tbl1){ref-type="table"}). Therefore, these genes should be systematically considered in the genetic diagnosis of Noonan syndrome.

Among the RAS subfamily members of the RAS/MAP kinase pathway reported in Noonan syndrome, *RIT1* seems to be the most involved gene compared with *KRAS* and *NRAS*, which have the lowest frequency among all reported cases (2.8% and 0.8%, respectively); however, among RAF family members, *RAF1* is the most involved gene compared to *BRAF* (8% versus 2.3%, respectively). Among these two families, neither *HRAS* nor *ARAF* were reported to cause Noonan syndrome. These divergences should attract more attention from researchers.

It is worth mentioning that there were no mutations in the *SHOC2*, *RRAS* and *CBL* genes in Noonan syndrome patients. These genes were reported to be involved in Noonan-like syndrome (NLS) only.

2.4. Inheritance and genetic counseling {#sec2.4}
---------------------------------------

Noonan syndrome is a common disorder that could occur as a sporadic condition or can be inherited in an autosomal dominant pattern. In the latter case, the affected parent who transmits the disorder is predominantly the mother. This may be explained by the adverse impact of Noonan syndrome on male fertility [@bib7], [@bib13], [@bib108]. However, rare autosomal recessive cases of Noonan syndrome with consanguineous parents have also been reported [@bib109].

When there is molecular evidence in one Noonan syndrome child, the clinical and molecular evaluation of parents becomes primordial in the determination of recurrence risks. In Noonan syndrome-causing genes with heterozygous mutations, the recurrence risk in one genetically affected parent is 50% per each pregnancy, while in an unaffected parent with Noonan syndrome child, the recurrence risk in subsequent pregnancies is very low, approximately 1--5% owing to putative germline mosaicism.

The Noonan syndrome patient and their family should be made aware of the consequences of some Noonan syndrome features that may arise or complicate with adulthood, such as fertility problems in cryptorchidism cases and cardiac and hematological complications, which need rigorous follow-up [@bib110].

The de-novo *PTPN11* mutations are known to be more recurrent in Noonan syndrome. Tartaglia et al suggested that de-novo mutations have a predominantly paternal origin. They also demonstrated that the paternal average age in sporadic Noonan cases was significantly higher than that of the general population [@bib111].

3. Conclusion {#sec3}
=============

Noonan syndrome is a common multigenic disease. Its clinical side has been profoundly discussed by several researchers and diagnostic guides as support has been developed. This review completes the efforts of researchers focusing on the genetic etiology side of this syndrome and explains the physiopathological intervention of different genes in the manifestation of Noonan syndrome traits. In the second part, this paper provides pediatricians and geneticists with the mutational prevalence of genes involved in Noonan syndrome, which was deduced from the analysis of most studies carried out so far.

The result of this prevalence analysis leads to interesting conclusions, in particular, the high mutation rates observed in *PTPN11*, *SOS1*, *RAF1* and *RIT1*, which cover 93% of reported mutations, suggesting that those genes should be systematically considered in the genetic diagnosis of Noonan syndrome. Secondly, we draw attention to the significant differences observed between mutational rates in genes of the same family (genes of the same level of the cascade). The explanation of this divergence and the other points discussed in this review may lead to new insights in the genetic research field of Noonan syndrome.
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